Asker Healthcare Group AB (publ) (STO:ASKER)
Sweden · Delayed Price · Currency is SEK | Market Cap | 30.78B -8.6% |
| Revenue (ttm) | 17.31B +11.2% |
| Net Income | 625.00M +54.7% |
| EPS | 1.63 +37.5% |
| Shares Out | 383.04M |
| PE Ratio | 49.24 |
| Forward PE | 26.05 |
| Dividend | 0.39 (0.46%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 291,305 |
| Open | 84.65 |
| Previous Close | 84.20 |
| Day's Range | 80.00 - 84.65 |
| 52-Week Range | 58.64 - 131.22 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 96.20 (+20.18%) |
| Earnings Date | Jul 21, 2026 |
About Asker Healthcare Group AB
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, ... [Read more]
Financial Performance
In 2025, Asker Healthcare Group AB's revenue was 16.79 billion, an increase of 11.73% compared to the previous year's 15.03 billion. Earnings were 492.00 million, an increase of 36.67%.
Financial StatementsNews
Asker Healthcare Group AB Earnings Call Transcript: Q1 2026
Strong Q1 performance with 13% sales growth and 21% adjusted EBITDA growth, driven by both organic expansion and accretive acquisitions. Margin improvement and robust cash flow support continued M&A, with stable leverage and positive outlook for 2026.
Asker Healthcare Group AB Quarterly report: Q1 2026
Asker Healthcare Group AB has published its Q1 2026 quarterly earnings report on May 6, 2026.
Asker Healthcare Group AB Slides: Q1 2026
Asker Healthcare Group AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Asker Healthcare Group AB Earnings Call Transcript: Q4 2025
Q4 saw 9% sales growth and a 16% rise in adjusted EBITA, with strong results in West and Central, and a 10% EBITDA margin achieved. Fourteen acquisitions expanded the footprint to 19 markets, and leverage remains stable, supporting continued M&A and a proposed 30% dividend.
Asker Healthcare Group AB Quarterly report: Q4 2025
Asker Healthcare Group AB has published its Q4 2025 quarterly earnings report on February 10, 2026.
Asker Healthcare Group AB Slides: Q4 2025
Asker Healthcare Group AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 10, 2026.
Asker Healthcare Group AB Annual report: Q4 2025
Asker Healthcare Group AB has published its Q4 2025 annual report on February 10, 2026.
Asker Healthcare To Acquire Allion Healthcare
(RTTNews) - Asker Healthcare Group AB (ASKER.ST), on Tuesday announced that it has signed an agreement to acquire shares of Allion Healthcare Inc. (ALLI), a manufacturer and distributor of medical sup...
Asker Healthcare Group AB Earnings Call Transcript: Q3 2025
Q3 saw 25% earnings growth and 15% sales growth, with strong results in West and Central, and a robust M&A pipeline. Leverage remains within target, and underlying organic growth is solid across regions, despite lumpy defense sales in North.
Asker Healthcare Group AB Quarterly report: Q3 2025
Asker Healthcare Group AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Asker Healthcare Group AB Slides: Q3 2025
Asker Healthcare Group AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Asker Healthcare Acquires InnoMedicus; Expects To Contribute Positively To EBITA Margin
(RTTNews) - Asker Healthcare Group (ASKER.ST) has acquired 100 percent of the shares in InnoMedicus AG, a distributor specialising in devices and solutions for precise diagnostics and minimally invasi...
Asker Healthcare Group AB Earnings Call Transcript: Q2 2025
Q2 saw 12% adjusted EBITDA growth (after FX), 9% sales growth, and a 9.5% EBITDA margin, with strong M&A activity and a robust pipeline. Region West and Central delivered strong results, while North faced headwinds from lower project-based sales.
Asker Healthcare Group AB Quarterly report: Q2 2025
Asker Healthcare Group AB has published its Q2 2025 quarterly earnings report on July 22, 2025.
Asker Healthcare Group AB Slides: Q2 2025
Asker Healthcare Group AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 22, 2025.